COVID-19 Information • Employee Health FORM • Fall Semester INFO
Main Menu

Cancer scientist Jim Cherry ’96 named by Governor Justice to BOG

Dr. James M. Cherry ’96

Dr. James M. Cherry ’96, a cancer scientist with the National Cancer Institute (NCI) in Frederick, Maryland, has been named to the Shepherd University Board of Governors for a four-year term by Governor Jim Justice.

Cherry, who received his Bachelor of Science degree from Shepherd in 1996, serves as the scientific program director and scientific advisor, Office of Scientific Operations, Office of the Director at the National Cancer Institute. His field of study is in women’s health, where he researches the molecular changes in ovarian tumor progression and has identified potential biomarkers that have proven useful in early diagnosis and prognosis that often elude detection until it has reached a very advanced stage.

He earned a Master of Science in molecular biology from Johns Hopkins University in 2000 and his Ph.D. in biology with a concentration in biomedical science from Catholic University of America in collaboration with the National Cancer Institute in 2007.

“We are most fortunate to have Dr. Cherry join the board at this time in Shepherd’s history,” said President Mary J.C. Hendrix. “His vision for excellence and strategic planning will help us transform our future.”

Cherry joined Qiagen in 2008 as a research fellow in its gene expression laboratory. Following his research fellowship, he was promoted to a research scientist in Qiagen’s research and development laboratory, where he worked on Qiagen’s SYBR-Green chemistry miRNA technology, miScript, for high-throughput molecular profiling. This newly developed automated application for gene expression was marketed to the biomedical research community, where Qiagen’s new product generated $5.2 million in sales in year one.

Cherry was recruited back to NCI in 2010 as a scientific program director of the Advanced Technology Program (ATP), and the contracting officer representative for the $800 million operational technical support contract for the NCI’s Division of Intramural Research. ATP, now Cancer Research Technology Program (CRTP), is currently an $18 million program that provides state-of-the-art technologies to NCI’s principal investigators and postdoctoral and clinical fellows at NCI and other federally funded research institutes. Cherry established a $4 million technology development effort for ATP in 2010. This program collaborates closely with NCI/NIH investigators to develop novel technologies in areas of biomedical research, including genetics/genomics, protein expression, proteomics, imaging (subcellular, cellular, and whole-animal), nanotechnology, genetically engineered animals, veterinary histology/pathology, and bioinformatics. In addition to his responsibilities overseeing ATP, Cherry was named the scientific program director for the Laboratory of Animal Science Program and the Advanced Biomedical Computing Center in 2013.

Cherry has also served as the scientific advisor for NCI since 2010 for graduate, undergraduate, and high school students at NCI in both Bethesda and Frederick. During this time, he has established academic partnerships, internships, and capstone opportunities with several universities, including Shepherd, Hood, Mount Saint Mary’s, Towson, and University of Maryland.